Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 2/20 | 0.58 |
| ▸ | HTR2C known ✓ | P28335 | 2/20 | 0.53 |
| ▸ | MAOA known ✓ | P21397 | 2/20 | 0.53 |
| ▸ | PDE4B known ✓ | Q07343 | 1/20 | 0.52 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.48 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.48 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.48 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.48 |
| ▸ | HTR1E known ✓ | P28566 | 1/20 | 0.48 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.48 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.48 |
| ▸ | HTR5A known ✓ | P47898 | 1/20 | 0.48 |
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.48 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3552712 | 0.98 | HTR3A (0.59) | HTR3AHTR2CMAOAPDE4BTDP1 | |
| SCHEMBL28488068 | 0.98 | HTR3A (0.59) | HTR3AHTR2CMAOAPDE4BTDP1 | |
| Hydrochloric Acid SCHEMBL568418 | 0.91 | HTR2A (0.54) | HTR3AHTR2CMAOAHTR2AHTR6 | |
| Hydrochloric Acid SCHEMBL16446233 | 0.90 | CYP2D6 (0.51) | HTR3AMAOAPDE4BTDP1HTR2A | |
| SCHEMBL28301764 | 0.89 | HTR2A (0.55) | HTR3AHTR2CMAOAHTR2AHTR6 | |
| SCHEMBL2145393 | 0.89 | HTR2A (0.55) | HTR3AHTR2CMAOAHTR2AHTR6 | |
| Hydrochloric Acid SCHEMBL2800981 | 0.89 | HTR2C (0.65) | HTR3AHTR2CMAOATDP1KDM1A | |
| SCHEMBL1015494 | 0.89 | HTR3A (0.50) | HTR3AHTR2CMAOAPDE4BHTR1A | |
| SCHEMBL16874793 | 0.88 | CYP2D6 (0.53) | HTR3AMAOAPDE4BHTR2AHTR6 | |
| SCHEMBL239790 | 0.87 | HTR2C (0.64) | HTR3AHTR2CMAOATDP1HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111936488-B | Novel compounds for the treatment of parasitic infections | 葛兰素史克知识产权开发有限公司 | 2023-06-27 | — | — | CN | disclosed |
| US-11453657-B2 | Compounds for the treatment of parasitic infections | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-09-27 | — | — | US | disclosed |
| EP-3743419-B1 | NOVEL COMPOUNDS FOR THE TREATMENT OF PARASITIC INFECTIONS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-09-14 | — | — | EP | disclosed |
| US-20210047299-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF PARASITIC INFECTIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-02-18 | — | — | US | disclosed |
| EP-3743419-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF PARASITIC INFECTIONS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-12-02 | — | — | EP | disclosed |
| CN-111936488-A | Novel compounds for the treatment of parasitic infections | 葛兰素史克知识产权开发有限公司 | 2020-11-13 | — | — | CN | disclosed |
| WO-2019145360-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF PARASITIC INFECTIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-08-01 | — | — | WO | disclosed |
| US-8003649-B2 | Bicyclic derivatives for use in the treatment of androgen receptor associated conditions-155 | ASTRAZENECA AB (SE) | 2011-08-23 | — | — | US | disclosed |
| EP-2235010-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS | AstraZeneca AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| US-20100016279-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155 | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
| WO-2009081197-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11453657-B2 | Compounds for the treatment of parasitic infections | PIGO, SGMS2, ABCB11 | HTR3A 4645/4885HTR2C 4693/4885MAOA 2701/4885 |
| US-20210047299-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF PARASITIC INFECTIONS | PIGO, ENPP2, THPO | HTR3A 4719/4885HTR2C 4686/4885MAOA 3778/4885 |
| US-20100016279-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155 | AR, NR5A1, CYP17A1 | HTR3A 432/4885HTR2C 528/4885MAOA 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.